RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

<<"the internal state of the CNS pharma industry." The latter should not be the cause of Corx's difficulty in forming an RD partnership (for indications with no current treatment, and similarly, no competition)>>

That's an absurd conclusion.You don't think that the internal state of CNS Pharma industry (partly in response to macro 'flux' in the economy, health care policy, and regulatory bodies) does not have an impact upon partnership tactics, choices, and timeframes in specific areas? Or to put it another way: You think that the level of competition in a specific therapeutic area can insulate Business Development in that area from the effects of these factors?

Give that some thought.

NeuroInvestment